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Lewis C CantleyLewis Cantley graduated from West Virginia Wesleyan
College in chemistry and took his PhD in biophysical
chemistry at Cornell University where he worked on
enzyme kinetics. He did his postdoctoral studies at
Harvard University where he stayed as an assistant
professor until he moved to Tufts University where he
discovered phosphoinositide-3-kinase, the enzyme
critical to the control of growth that has dominated his
research ever since. He returned to Harvard as a
Professor of Cell Biology and later as a member of the
new Department of Systems Biology and is now
Director of the new Cancer Center at Weill Cornell
Medical College and New York-Presbyterian Hospital.Lewis CantleyQuite early in your research career, you
discovered the enzyme phosphoinositide kinase -
usually known as PI3K - whose crucial activities
are still central to your research. Can you briefly
say what it does?
PI3K generates a lipid - and a lipid that wasn’t known
prior to our discovery. It’s a very minor lipid - that’s why
it had been missed - that is the product of inositol phos-
phorylation mediated by PI3K. Even at the time of our
discovery that PI3K makes this novel lipid, we already
had evidence that high levels of this enzyme correlated
with malignant transformation of cells: in collaborations
with Tom Roberts, Brian Schaffhausen and Ray Erickson
we had shown that viruses that cause cancers in mice
and chickens often do so by activating this novel enzym-
atic activity. So we knew early on that well-studied viral
oncoproteins such as Src and polyoma middle T activate
this lipid kinase. We went on to show that the product
of PI3K, phosphatidylinositol-3,4,5-trisphosphate (PIP3),
was quite high in cells transformed by these viruses. Be-
cause of its correlation with cancer, we suspected very
early on that PIP3 was an oncolipid - although we didn’t
actually name it that.Correspondence: lcantley@med.cornell.edu
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stated.So the connection with cancer was established
very early on and then, in an overview of PI3K
signaling that you wrote in 2002 [1], you
predicted that studies on the PI3K pathway would
lead to new targets for diabetes and cancer. Did
you realize then that metabolic disturbances like
diabetes and cancer might actually be linked?
Well, we did because we published a paper in 1990 where
we reported that not only was PI3K activated by growth
factors like EGF and PDGF, but it was also activated by
insulin [2]. In fact, insulin turned out to be the very best
way to activate it. As we continued to pursue that finding
through the very early 1990s, we and others found that
virtually everything that insulin did required the activity
of PI3K. In other words, inhibitors of PI3K or knockouts
of PI3K in mice abrogated insulin signaling. Insulin-
dependent glucose uptake, for example, required PI3K.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tems - on cell lines and mouse knock-outs - other labs
were studying worms and flies, and the gene encoding
PI3K popped up in genetic mutants of flies, in a pathway
that was downstream of the insulin/insulin-like growth
factor (IGF) receptor. While mammals have separate but
related receptors for insulin and IGF1, flies and worms
have a single receptor that is the ancestor of these two
receptors. So PI3K showed up genetically in the insulin/
IGF-1 signaling pathway that controls cell growth in
flies. In worms, it popped up in a nutrient-dependent
age-related phenotype. In fact, it was called 'age-1' before
it was identified as PI3K because loss-of-function muta-
tions in the gene dramatically extend the lifespan of
worms. The genetic network for ageing turned out to be
the insulin receptor, IRS-1, PI3K, AKT, FoxO network -
the same network that we were uncovering in mamma-
lian systems.
So it was very clear by the late 1990s that PI3K
evolved as a mediator of insulin/IGF-1 receptor signal-
ing. And as full genome sequences of flies and worms
became available it became clear that while the insulin
receptor-PI3K-AKT-FoxO pathway was well conserved,
other pathways for activating PI3K that we had found in
mammalian cells were less conserved. And that led us to
conclude that PI3K and PIP3 originally evolved to me-
diate insulin/IGF-1 signaling and to control nutrient up-
take - particularly glucose uptake in response to feeding
- and distribute it into the appropriate tissues for the
organism to grow.
What you are mostly focused on now is specific
disturbances of growth-related signaling net-
works in tumor cells that might suggest new drug
targets, and I’d like to ask you about one notice-
able thing about these studies - the frequent dis-
covery of apparently paradoxical results. Would
you like to say why these studies so often throw
up paradoxes?
I think what we’re learning, of course, is that biological
systems are far more complicated than we’d imagined. As we
acquire tools that allow us to acutely knock out or knock
down the expression of a particular gene, or have a drug that
inhibits a particular step in a metabolic pathway or signaling
pathway, we are finding that the system responds to these
perturbations by attempting to reactivate the pathway. In
other words, a lot of what we call robustness in nature comes
about because biological systems have numerous negative
feedback regulatory networks that sense when the system is
out of balance and become altered to restore homeostasis.
So some of the paradoxes come from the fact that whenever
you inhibit a component of a signaling or metabolic network,
you end up reactivating things upstream of it, giving a result
that’s the opposite of what you expected to see.In metabolic networks particularly, it’s been known for
a long time that there are all kinds of feedback control.
One example of a paradox from our research was the
observation that pyruvate kinase, which is the enzyme in
glycolysis that synthesizes ATP, actually tends to get
turned down in cancer cells. This is paradoxical because
cancer cells are typically utilizing glucose at 50- to 100-
fold the rate of the normal tissue surrounding it, so why
would they want to turn down one of the steps in that
pathway and make less ATP? In the end, we figured out
that it’s because that allows the cells to use the interme-
diates in glycolysis for other purposes than just making
ATP, such as making NADPH, or making ribose, or
making serine or glycine [3].
These are for biosynthetic pathways?
That’s right. The cancer cell of course needs to grow,
and it needs to be able to control its oxidation-reduction
potential. Those are typically a greater challenge for a
cancer cell than just making ATP, which it can do
through oxidative phosphorylation in mitochondria. So
if you turn down ATP synthesis through glycolysis
because you’re using glucose intermediates for metabolic
processes, you can make up for that in the mitochondria
and the cell is fine.
So would you conclude that you really need to
know your way around metabolism before you
can start to predict what will happen if you
interfere with a particular step in the pathway?
That’s right. It’s only now that we have the tools to
acutely perturb metabolic systems and monitor what
happens, and we can really begin to understand the
wiring diagrams of these pathways.
I’d like to ask you one last question, on fructose.
You’ve written recently on the very topical issue
of whether fructose is a particularly important
cause of metabolic disease [4] and, as we now
know, with possible very strong links to cancer.
As I understand it, sucrose - and even other car-
bohydrates - in excess can be metabolized to fruc-
tose. So if we’re just eating too much
carbohydrate generally, does it really matter
whether it’s fructose or any other kind?
It turns out that it does matter. Quite honestly, four or
five years ago I was in your camp of assuming, you know
- fructose, glucose, they have exactly the same number
of calories per gram, they can be interconverted instantly
inside most cells, so what does it matter? The answer is,
it’s really important - and quite striking - because the
liver differentially metabolizes fructose and glucose. This
specialization is pretty much unique to the liver; in any
other cell, the fructose and glucose are pretty much
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kinase, so it cannot phosphorylate fructose at the six
position. This is in contrast to glucose, which can be
phosphorylated at the six position in the liver by gluco-
kinase to make glucose-6-phosphate, which is then con-
verted to fructose-6-phosphate. And that is then
phosphorylated at the one position by phosphofructoki-
nase (PFK), which is - and here’s the key point - the ul-
timate gatekeeper for entering glycolysis. In contrast,
fructose that enters the liver is phosphorylated at the
one position by fructokinase (also called ketohexokinase)
to make fructose-1-phosphate rather than fructose-6-
phosphate. The liver is almost unique in regard to the
ability to differentially metabolize glucose and fructose.
And that matters because…?
That matters because once it’s phosphorylated at the
one position, fructose can be a substrate for aldolase,
and shoot down the glycolytic pathway, bypassing the
gatekeeper PFK, which is the control step for going into
glycolysis. In most tissues, if the cell finds itself with
plenty of ATP and plenty of citrate (the building blocks
for making fatty acids), it will stop all flux through gly-
colysis because ATP and citrate inhibit PFK - a classic
example of a metabolic negative feedback control. So the
glucose that enters the cell can still get phosphorylated
but it doesn’t go down glycolysis and doesn’t get con-
verted to fat but rather gets stored as glycogen or exits
the cell.
But in the liver, fructose bypasses that whole machin-
ery, because it doesn’t need PFK; it gets phosphorylated
at the one position directly, without phosphorylation of
the six position first and, as a consequence, now be-
comes a substrate for aldolase, and it produces even
higher levels of ATP and citrate that go on to make fatty
acids. No matter how much you’ve eaten, you will still
make more fat if you eat fructose.
There are two other things about fructose that make it
different from glucose. One is that all the fructose you
eat is cleared on its first pass through the liver. In other
words, the liver scarfs up all the fructose and immedi-
ately converts it to fat, while glucose stays in the blood-
stream for some period of time. That’s why we call
starches hyperglycemic molecules; they keep glucose
levels in your bloodstream high for a long time. That is
good for the brain - the brain loves to eat glucose. It’s
good for the muscle. But fructose doesn’t actually supply
any energy to your brain at all, it doesn’t supply any en-
ergy to your muscle; it only gets stored as fat. That’s
really quite remarkable, if you think about it. You eat su-
crose - one molecule of glucose and one molecule of
fructose - that glucose is being used by your muscle and
your brain - your brain loves getting that glucose - but
the fructose is all just getting stored as fat.But does it also mean that you get hungrier - you
want more sugar if you’re using fructose rather
than glucose?
Exactly. You would have to eat exactly twice as much
sucrose as starch to get the same amount of energy sup-
plied to your muscle and brain. The brain realizes that,
it keeps relaying a feedback so that the more sugar you
eat, the more it wants you to eat. Hence the addiction to
sweetness. That’s the dangerous thing about this
molecule.
You might ask - well why did we evolve such a com-
plicated system? Why does only the liver feed fructose
straight into fat? I think it’s quite clear why this happens.
We have a symbiotic relationship with plants. Plants
want to spread their seeds around, so they surround
them with fructose. High-fructose material surrounding
the seeds gets us and other animals to eat them and this
craving of fructose makes us eat them a lot and we end
up carrying their seeds around and spreading them. But
at the same time, it gives us an advantage because those
fruits ripen just at the end of the growing season, which
generally means, in almost all environments, that you’re
not going to have much to eat over the next few months.
So the best way to survive is to convert everything you
eat at that time into fat. That is the long-term storage
mechanism that allows you to survive until the next
growing season. That’s why fructose was spectacular for
us 10,000 years ago, getting us through these famines
that we faced every year. But today we don’t have fam-
ines and so we just get fat.
Does this put a whole new gloss on Eve and that
apple?
You’d probably have to eat about a bushel of apples to
get the same amount of fructose as in a 40 oz Coke,
which we’re trying to ban here in New York City
unsuccessfully.
And here’s an additional comment. The way we’ve
attempted to avoid this problem is by using artificial
sweeteners. The problem with those is that a disconnect
ultimately develops between the amount of sweetness
the brain tastes and how much glucose ends up coming
to the brain.
So the brain figures you have to eat more and more
and more sweetness in order to get any calories out of
it. The consequence of people eating lots of sweeteners,
no matter what they are - whether they’re natural or un-
natural - is that it increases the addiction for the sweet-
ness. As a consequence, at the end of the day, your brain
says, 'OK, at some point I need some glucose here'. And
then you eat an entire cake, because nobody can hold
out in the end. The only way really to prevent this prob-
lem - to break the addiction - is to go completely cold
turkey and go off all sweeteners - artificial as well as
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